Disability Elimination Period

In insurance, the elimination period (also known as waiting period) is the time between the onset of a disability and when the policy's benefits start to be paid out. The purpose of the elimination period is to avoid paying out for temporary disabilities, and to avoid moral hazard where individuals are incentivized to take out insurance only when they anticipate a short-term disability.

A disability elimination period can range from a few days to several months, and can be customized to fit the policyholder's needs. A shorter elimination period will typically result in higher premiums, as the insurance company is at a higher risk of having to pay out benefits.

Here's an example: John has a disability insurance policy with a 30-day elimination period. He becomes disabled and is unable to work on January 1st. His policy benefits will start to be paid out on February 1st, 30 days after the onset of his disability.

Key features of a disability elimination period include:

  • The length of the elimination period can be chosen by the policyholder when the policy is purchased.
  • A longer elimination period will typically result in lower premiums, as the insurance company is at a lower risk of having to pay out benefits.
  • The elimination period applies each time the policyholder becomes disabled, not just once.
  • The elimination period only applies to disabilities that are covered by the policy.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.